Form 4: Ligand Pharmaceuticals' President & COO Matthew Korenberg Sells Shares

Matthew Korenberg, President & COO of Ligand Pharmaceuticals, recently sold shares of the company's common stock in a series of transactions.

Summary

• On August 22, 2024, Matthew Korenberg sold 1,157 shares of Ligand Pharmaceuticals' common stock at a weighted average price of $105.54.
• On August 23, 2024, he sold 2,037 shares at a weighted average price of $104.0945 and 4,275 shares at a weighted average price of $105.1319.
• On August 26, 2024, Korenberg sold 6,177 shares at a weighted average price of $105.016 and 5,212 shares at a weighted average price of $106.3214.
• Following these transactions, Korenberg directly owns 49,510 shares of Ligand Pharmaceuticals' common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider selling. The sentiment is neutral as it simply reports transactions without expressing any opinion on the company's performance or future prospects.

Industry Context

Insider selling can be interpreted in various ways by the market, but it is a common occurrence and doesn't necessarily indicate negative prospects for the company.

Stakeholder Impact

• Shareholders may react to the news of insider selling, although it is a common occurrence.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal.

Key Dates